



PBI Pressure BioSciences Inc.

Ticker: PBIO (OTCQB)

Corporate Profile

as of November 27, 2015


Pressure BioSciences, Inc. (PBI) is a medical research products and services company. PBI, based in South Easton, Massachusetts, serves researchers at academic laboratories, government agencies, biotechnology, pharmaceutical, and other life sciences companies. PBI develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. The market for PBI consists of an estimated 500,000 scientists in over 80,000 research laboratories worldwide. PBI's development and sales efforts are in the biomarker discovery, drug discovery/design, and forensics areas. Potential customers could be expanded to areas such as: bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications. With these potential target areas, the growth potential for PBI is exponential. The US medical device industry is expected to grow to \$133 Billion by 2016 (Source: Selectusa.commerce.gov). PBI holds 14 US and 10 foreign patents covering applications of PCT that offer significant advantages over competitive methods.

PBI produces products that are based on constant (i.e., static) and alternating (i.e., Pressure Cycling Technology, or PCT) hydrostatic pressure that help to control the actions of molecules in biological samples. The company offers products such as Barocycler Instruments, Shredder System and PULSE Tubes. PBI's Pressure Cycling Technology is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. PBI has installed over 250 PCT systems in approximately 160 sites worldwide. PBI has recently held on-going discussions with large potential strategic partners, which offer a tremendous potential for growth for the firm. In August 2015, DM WDM, one of Central and Eastern Europe's leading small cap investment banks, announced the exchange of 1M shares of PBI (valued at \$0.50/share) for 601,500 shares of Everest Investments Holdings, the formation of Pressure BioSciences Europe, and \$250,000 of U.S. market support for PBI. Everest is run by one of Poland's most recognized and respected fund managers. In August 2015, PBI announced the start of a two-year collaboration with the Institute of Bioinformatics, one of India's most prestigious scientific research organizations, focused on the use of PBI's PCT platform for the discovery of molecular biomarkers in a number of diseases and disorders, including cancer and stroke.

PBI is well positioned for continued growth with the introduction of newly enhanced products, a growing industry and expanded marketing initiatives. Strong management and solid sales growth over the previous year has slated PBI for a positive outlook for enabling continued future growth. Indeed we anticipate PBI can soon surpass its 52-week high in share price.



Income Statement	FY 2013	FY2014	Sep-15	Balance Sheet	FY 2013	FY2014	Sep-15	Cash Flow Statement	FY 2013	FY2014	Sep-15
Revenue	1,503,288	1,374,744	1,433,572	Cash & cash equivalents	31,417	473,948	76,875	Operating Cash Flow	(2,342,603)	(3,210,578)	(2,679,949)
Gross Profit	478,850	697,712	598,611	Total Assets	1,103,282	1,744,132	2,210,988	Investing Cash Flow	(58,749)	(7,139)	(6,662)
Operating Loss	(3,327,192)	(3,338,350)	(2,629,436)	Total Liabilities	3,071,057	3,803,863	6,702,877	Financing Cash Flow	2,431,308	3,660,248	2,289,538
Net Loss	(4,084,427)	(4,612,540)	(3,430,160)	Total Shareholder's Equity	(1,967,775)	(2,059,731)	(4,491,889)	Cash at end of period	31,417	473,948	76,875



Sector: Healthcare
 Industry: Medical Appliances & Equipment
 Website: www.pressurebiosciences.com

Key Statistics

Price 11/27/2015	0.330
52 Week High	0.45
52 Week Low	0.1625
Avg. Vol (30day)	59,274.0
Beta	0.99
Market Cap (Interday)	7.07M
Market Cap/Sales (TTM)	4.11
Institutional Ownership (%)	0%
Insider Ownership (%)	10.3%
Shares Outstanding (M)	21.49
Float (M)	18.00
EPS(ttm)	-0.26

Source: Cap IQ/Google Finance

Recent 2015 Highlights

- PBI announced the close of an additional \$745,000 in a \$5M PIPE; funding total to date exceeds \$4,000,000.
- PBI announced Q3 2015 financial results, including record revenue for the quarter and nine-month periods ended September 30, a 55% increase in total revenue compared to the same quarter in 2014, and a 13.4% decrease in operating loss for the third quarter of 2015.
- In a Q3 conference call, management gave guidance that it anticipates record revenues to continue into 2016.
- Total revenue for Q2 2015 was \$413,104 as compared to \$307,464 for the same period 2014 - an increase of 34%.
- PBI announced in October, a collaboration agreement with Florida International University to co-develop an improved rape kit test method, based on the PBI's PCT platform to aid in an estimated backlog of untested rape kits.

Corporate Contact Information

Pressure BioSciences Inc.
 Richard T. Schumacher, CEO
 14 Norfolk Ave. South Easton MA, 02375
 Phone: 508-230-1828
www.pressurebiosciences.com